Steady Compounders: 6 Under-the-Radar Stocks for Your Buy List
May 20, 2025
11 min read
Steady Compounders — Six Under-the-Radar Stocks for Your Buy List
Forget «moonshots» and supposed value bargains — real wealth building happens quietly, between value trap and growth trap. Six barely noticed steady runners are anything but spectacular — but unstoppable. Our original analysis for The Market by NZZ — plus the extended investor's view for arvy readers.
The thesis on video — 1 minute
In 30 seconds — the core thesis
- Investors are obsessed with two extremes: the next big thing (moonshots, disruptors) and apparent bargains (deep value). Both hide hidden traps.
- Value traps and growth traps are the two risk classes investors systematically underestimate. When value disappoints, markets are sour. When growth disappoints, they are merciless.
- The "quiet middle path" is the steady compounder — businesses with moderate growth, reasonable valuations, robust moats. Barely noticed because unspectacular. Exactly that's why the mathematically and psychologically superior path.
The original analysis — the opening
The next big thing: investors are obsessed with it.
Whether it's the much-watched tech unicorn, the latest disruptor, or a potential «game changer» — everywhere people are searching for the next big hit. On the other side of the investment spectrum stand the so-called «deep value plays»: companies whose valuations seem so low that you can hardly ignore them.
Both extremes carry risks. And with risk come two well-known terms: «value traps» and «growth traps».
Time to look closer.
Value traps are familiar territory for value investors: a stock comes under pressure. The valuation looks tempting — almost too good to be true. A few dark clouds on the horizon? They'll surely pass. Or won't they? Wrong thinking. Fundamentals disappoint again. The problems aren't temporary — they're structural. The price falls further, and for good reason. Cautionary examples of value traps fill the textbooks and lecture halls of finance schools worldwide.
But there's another, less known — and possibly more dangerous — relative: the growth trap. Here the temptation lies in the story. Disruption. The «total addressable market» is huge. Technological breakthroughs. Hypergrowth. Moonshots. And investors fall in love with these stories.
But growth stocks are by no means immune to disappointment — on the contrary: they are particularly vulnerable, especially when the market cycle turns against them. And when it does? The market doesn't hesitate. The punishment is brutal.
→ Read the full article with the six concrete stock picks on The Market by NZZ
Chart 1: When value disappoints, markets are sour. When growth disappoints, they are merciless.
Source: NZZ The Market
01The uncomfortable question: why do so many investors chase the extremes?
The logic that the "quiet middle path" — steady compounders with moderate growth, reasonable valuations, robust moats — is the mathematically superior path is intellectually easy to accept. The uncomfortable question that doesn't fit into an NZZ column with depth is another: why then do so few investors do exactly that? Why instead do value chasing and growth chasing dominate most retail portfolios — even with investors who intellectually know that steady compounders are superior?
The answer is psychological, not intellectual. Three mechanisms systematically pull investors into the extremes:
- Story hunger. Steady compounders have no exciting story. "My business has been growing 9–13% for 20 years" is not a lunch table highlight. "I found the next Tesla" or "this bank is 30% undervalued" are tellable stories. Investors chase tellable stories because the emotional need for meaning fuses with investing.
- Time preference. The value of a steady compounder unfolds over 15–25 years. The "win" of a moonshot bet shows itself (or doesn't) in 12–24 months. Even when the long-term math clearly favours steady compounders, most people prefer faster feedback — even if expected returns are lower.
- Survivorship bias. The success stories of moonshot investors are celebrated (Cathie Wood 2020, early Tesla investors). The ten-times-more-frequent losses are forgotten. This asymmetric reporting dramatically distorts the perceived success probability in favour of the extremes.
The "boring is good" advantage
Exactly because the middle path is unspectacular and psychologically unattractive, it has structural valuation advantages. Fewer investors push into these stocks, so they trade at more reasonable multiples. Fewer fads, so less drastic drawdowns. Less volatility, so better holding periods. Over 20 years this advantage compounds dramatically — not because the underlying businesses are better than hypergrowth, but because the valuation and holding-period reality is more favourable for investors. The "boring is good" effect is not magic. It's anti-selection.
02Value trap, growth trap, steady compounder — the three archetypes
To identify the "quiet middle path", investors need a clear mental picture of all three archetypes — what distinguishes them, how to recognise them, and why different risk mechanics apply to each:
Trap 1
Value Trap
"Cheap looks like a bargain" — but structural problems are real and getting deeper. Valuation bargain that's rightly cheap. Classic in structurally losing sectors.
The quiet middle path
Steady Compounder
Reasonable valuation, moderate organic growth (typically 7–15%), robust moat, stable margins. Unspectacular and barely noticed. The real wealth-building machine.
Trap 2
Growth Trap
"Exciting story justifies any price" — but when growth disappoints, drawdowns are brutal. Multiple reset from 80× to 25× is a halving — without the business ever having fallen.
How to recognise value traps
Three questions that almost unmask any value trap: (1) Are the structural trends in the industry friendly or hostile to the business? A bank in a negative interest rate environment, an energy provider in an energy transition country, an auto supplier in EV transition has structural headwinds that won't "go away". (2) Has management strategically reinvested cash flow in the last 5 years or simply distributed dividends and bought back stock? Pure capital distribution in structurally shrinking businesses is liquidation in slow motion. (3) Are margins stable, slightly rising, or creeping down over the last 5 years? Creeping margin erosion is the clearest early signal of structural weakness.
How to recognise growth traps
Three questions that almost unmask any growth trap: (1) How high are valuation multiples in absolute terms and historical comparison? When a business trades at 50× earnings because growth is 35% and the historical premium level was 30×, the multiple-reset probability is high. (2) How much does the investment case depend on growth-above-expectations? Businesses that "only" need to meet expectations are robust. Those that need to exceed them are fragile. (3) How much of the valuation comes from real cash flows of the next 3 years, and how much from expected cash flows in 5–10 years? The further the cash flow expectation is shifted into the future, the more fragile the valuation.
How to recognise steady compounders
Four criteria together: organic growth 7–15% (cf. Trees Don't Grow to the Sky), stable or rising operating margins over at least 5 years, robust moat (ideally multiply validated), valuation below the 5-year premium level of the business itself. Such businesses exist in every sector — but they are rare in mainstream top topics. The search takes weeks but pays off for any long-term investor.
The brutal asymmetry
Thierry's NZZ chart shows it clearly: when value disappoints (e.g., earnings miss), the market reacts with moderate drawdowns of 10-20%. When growth disappoints, it reacts with brutal drawdowns of 30-60%. That's the mathematical consequence of multiple sensitivity: a multiple reset from 60× to 30× halves the stock price even with stable earnings. At a multiple of 12× the downside room is much smaller. This asymmetry is not "psychological market reaction" — it's the mathematical result of valuation structure.
03What this means for your quality portfolio
The steady compounder logic is one of the most pragmatic application lenses in quality investing. It helps with the most important selection step: which businesses are real compounders, which only apparent ones? Three structural questions every investor must answer when building a steady compounder portfolio:
First question — sector diversification done right. Steady compounders exist in almost every sector, but the concentration is unevenly distributed. Consumer staples, industrial mid-caps, regulated utilities, specialty chemistry, healthcare subsectors typically produce many steady compounders. Semiconductor hypergrowth subsectors, biotech early-stage, platform tech few. Anyone building their steady compounder portfolio from three sectors has structurally too little diversification.
Second question — geography matters. Steady compounders are globally distributed but differently priced. Swiss and European steady compounders often trade at 15–25% discount to US peers — not because they're worse, but because US investors pay home-premium. Anyone saying "buy steady compounders" should actively check whether they don't have 70-80% in one geography.
Third question — position sizing. Steady compounders lose their effect when held as 0.5% positions. They need 3-8% position size so the compounding contributes meaningfully to portfolio performance over 15-20 years. That means: a concentrated steady compounder portfolio has 12-20 positions, not 50. Anyone with 50 positions is doing index investing with high costs — not steady compounder investing.
| Investor profile | Typical steady compounder allocation | What to review |
|---|---|---|
| "I follow the MSCI World" | Low — many steady compounders aren't in top-50 index positions | Selective admixture as conscious quality tilt |
| "I focus on hypergrowth" | Very low | Structural gap in compounding zone — consider deliberate build-up |
| "I buy Swiss standards" | High (Nestlé, Roche etc. are classic steady compounders) | Diversification across sectors and geographies — not just 3-5 Swiss mega-caps |
| "I'm engaged in quality compounders" | Majority of portfolio | Hold discipline, regular valuation reviews, check position sizing |
How this steady compounder logic is applied in practice in stock selection — and why disciplined quality investors often prefer the seemingly boring businesses to the spectacular ones — is deepened in our pillar article The Tortoise Problem: Why Quality Wins. The concrete arvy allocation is in the Q1 2026 Quarterly Report.
04Three scenarios for steady compounders
Steady compounders show their strengths over long periods — the next 18 months are less decisive than the next 10 years. But for the question of entry, build-up, or holding, plausible paths help:
Bull Case
Re-discovery of steady compounders after AI hype consolidation
A consolidation of the AI hype wave leads to multiple resets in hypergrowth, simultaneously to re-allocation into quality. Steady compounders trading at reasonable valuations today benefit above-average — both through operative compounding and through slight multiple expansion. Disciplined investors who built up gradually today reap above-average returns over 24–36 months.
Base Case
Steady operative compounding returns, occasional multiple swings
The majority of steady compounders deliver their typical returns — operative growth 9–13% plus dividend, occasional multiple swings depending on market sentiment. Over 20 years these businesses compound at 12–18% annually, with significantly smaller drawdowns than broad indices. Our base case.
Bear Case
Multi-sector correction — steady compounders also fall, but more moderately
A broad market correction — triggered by recession, geopolitical shock, liquidity crisis — hits all valuations. Hypergrowth loses 40–60%, broad indices 25–35%, steady compounders 15–25%. But the operative businesses keep working, dividends flow, moats hold. In the recovery phase steady compounders typically lead back first. Anyone who strategically bought in the correction has a long-term lead.
How disciplined investors navigate correction phases with steady compounder portfolios — and why psychological discipline in drawdowns decides long-term performance — is described in our pillar "Master Your Emotions When Investing".
05What you should review now
An honest steady compounder analysis of your portfolio is one of the most valuable 30 minutes you can take. Four concrete checks:
1. Archetype inventory of your top 10 positions. Go through your largest positions and assign each to one of the three categories — value trap, steady compounder, growth trap. For most investors this exercise reveals: 60–80% are in one of the two traps, 20–40% are real steady compounders. Is that the allocation you consciously chose?
2. Quiet middle path gap. How many real steady compounders (all four criteria from Section 02 met) are in your portfolio? If the answer is "fewer than 5", the wealth-building machine of your portfolio is weak. Gradual build-up would be sensible.
3. Geography and sector distribution. Are your steady compounders distributed across at least 4-5 sectors and 2-3 geographies? Or concentrated in 2-3 sectors? Real diversification in steady compounders is more important than in hypergrowth because drawdowns can be smaller but more persistent.
4. Position sizing reality. Are your steady compounders represented with sufficient position sizes (3-8% per position) so their compounding really contributes to portfolio performance? Or are they 0.5-1.5% mini positions that are irrelevant in portfolio context?
What disciplined investors do now
They don't panic-sell their hypergrowth or value positions to rotate into steady compounders — that would be strategy hopping. They look at their allocation honestly, identify real steady compounders on a watchlist, and gradually build up their steady compounder position based on new investments or savings plan amounts. Over 18-24 months the allocation shifts gradually. That's boring, less exciting to tell, and mathematically exactly what works. History rewards not the one who rotates most dramatically — but the one who patiently holds the unspectacular compounders.
06Frequently asked questions
Which six steady compounders does the NZZ analysis specifically mean?
The six concrete picks and the rationale are in the NZZ original article — we deliberately link there because that's contractually the place where these recommendations appear. What we do here on arvy.ch is the steady compounder mechanics behind it — the criteria by which we evaluate such businesses. Anyone wanting to read the picks can find them in the NZZ original.
Does arvy invest in exactly these six steady compounders?
The exact sector and single-stock allocation is communicated transparently in our quarterly strategy reports. Generically: arvy's strategy has always been geared toward quality compounders — the four criteria from Section 02 are our standard lens for stock selection. Which concrete positions this currently produces is documented in the arvy Q1 2026 Quarterly Report.
How do I distinguish a steady compounder from a value trap with growth?
The key distinction is structural trends. A steady compounder operates in a market with long-term tailwinds — demographics, consumer behaviour, regulatory stability, technological robustness. A value trap with growth operates in a market with structural headwinds that "haven't fully kicked in yet". The first early signals: creeping margin erosion, shrinking market shares in subsegments, defensive management reactions (cost-cutting, share buybacks instead of investments). When these signals appear, the apparent steady compounder is often an early-stage value trap.
Are classic Swiss quality stocks like Nestlé, Roche, Novartis steady compounders?
We don't give blanket single-stock recommendations. But generically: many classic Swiss quality champions historically meet the steady compounder criteria (organic growth 7-15%, stable margins, robust moats, often reasonable valuations). That's not a buy signal per se — valuation and company-specific factors remain decisive. But structurally they are the template for the steady compounder class. Applying the four criteria from Section 02 individually to each position is the disciplined way.
Further reading — the thematic anchors of this analysis
The Tortoise Problem
Steady compounders as the wealth-building class
arvy Quarterly Report Q1 2026
Current allocation transparently documented
Trees Don't Grow to the Sky
The 7-20% growth zone of steady compounders
Quality Is Dead, Long Live Quality
The five quality criteria as foundation
Master Your Emotions When Investing
Discipline through unspectacular phases
Investing with arvy: The Complete Guide
How this analysis fits the overall strategy
Real wealth building happens quietly
The notion that the next big investment idea — the ten-bagger, the disruption champion, the deep value bargain — is the source of serious wealth building dominates investment culture. It is wrong. Empirically wrong and mathematically wrong. Real, sustainable wealth building doesn't come from the extremes — it comes from patiently holding unspectacular steady compounders over very long periods.
The six stocks from the NZZ original are not "secret tips" — they are examples of a class of businesses that structurally represent the superior long-term investment. What separates the disciplined investor from the story-chasing retail investor is not access to better picks. It's the willingness to hold the unspectacular picks when everyone else chases the next moonshot. That's boring in daily experience and magical in two-decade hindsight. Exactly that's why it works. And exactly that's why it works for so few.
Original written by Thierry Borgeat, Co-Founder of arvy, for The Market by NZZ. The extended arvy companion piece reviewed by Patrick Rissi, CFA and Florian Jauch, CFA. Data sources: NZZ The Market, own analyses, academic literature on quality factor investing. Last updated: April 2026.
Disclaimer: This article is for general educational purposes and does not constitute personal investment advice. The security designations mentioned are illustrative and not buy or sell recommendations. Past performance is no guarantee of future results. Scenarios are assessments, not forecasts. arvy is a FINMA-supervised asset manager with a CISA licence (Art. 24). Imprint & Legal Notice.
